Clinical endocannabinoid deficiency (CECD) is a medical theory that proposes that a deficiency of endocannabinoids is the underlying pathophysiology of migraines, fibromyalgia, and irritable bowel syndrome. [1] [2] The deficiency may sometimes start in the womb as a result of maternal obesity. [3]
The nature of the syndrome and existence of CECD as a clinically meaningful condition have been called into question. [4]
References
- ^ Russo, EB (2004). "Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?". Neuro Endocrinology Letters. 25 (1–2): 31–9. PMID 15159679.
- ^ Russo, EB (2016). "Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes". Cannabis and Cannabinoid Research. 1 (1): 154–165. doi: 10.1089/can.2016.0009. PMC 5576607. PMID 28861491.
- ^ Schlabritz-Loutsevitch, N, et al. (2016). "Fetal Syndrome of Endocannabinoid Deficiency (FSECD) in Maternal Obesity". Medical Hypotheses. 96: 35–38. doi: 10.1016/j.mehy.2016.09.021. PMID 27959272.
- ^ Cogan, PS (2020). "Practical Considerations of Hypotheses and Evidence in Cannabis Pharmacotherapy: Refining Expectations of Clinical Endocannabinoid Deficiency". Journal of Dietary Supplements. 17 (5): 608–624. doi: 10.1080/19390211.2020.1769246. PMID 32449630.
 | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |